Asthma News – October 14, 2021
Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff.
Sign up to receive weekly-ish news emails.
Check out the most recent
MDHHS asthma social media messages and share them with your networks.
Asthma Educator Sharing Day 2021 is being split into TWO virtual Asthma Educator Sharing Times, to learn about current interventions and treatments for the management of asthma, and techniques to improve asthma education in all settings. Applications for 3 RN and RT contact hours/event pending.
Registration for Oct. 29 event still open!
A report from the Swedish National Airway Register found that The frequency of severe COVID-19 in asthma and COPD was relative low. Mortality for those hospitalized was double as high in COPD compared to asthma. Comorbid asthma and COPD were not always identified among patients with severe COVID-19.
NTM-LD was associated with use, dose, and duration of exposure to ICS; however, discontinuation of ICS for 120 days or more may significantly decrease the risk for NTM-LD, according to new study results. Low-, moderate-, and high-dose ICS were all found to be associated with the increased risk.
A new study examined early exposure to dozens of pollutants potentially experienced by children with mild to severe forms of the disease. While some cases could be linked to an individual, established air pollutant, others appeared to be linked to mixtures of pollutants that had never been associated with asthma.
Inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist/long-acting muscarinic receptor antagonist fixed-dose combination therapies appeared to be safe and effective for the treatment of uncontrolled asthma. The dose of ICS used in the combination therapies represents the discriminating factor for treating patients with a history of moderate or severe asthma exacerbations.
Asthma-related social media messages are now available, please share them within your personal or organizational networks!
Findings of a new study suggest that e-cigarette use is associated with more frequent asthma symptoms and disproportionally affects male asthmatics.
The report found that tezepelumab reduces exacerbations among patients who have severe asthma, including some types of asthma that lack other effective biologic therapies. It also yielded relatively small improvements in daily symptoms and quality of life, and models suggested it would exceed typical cost-effectiveness thresholds.